Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial

What Was Tested

The paper reports a study of Parathyroid Hormone (PTH 1-84), published as a randomized controlled trial.

Vitamin D deficiency/insufficiency is common in chronic kidney disease (CKD) patients and it contributes to secondary hyperparathyroidism, which occurs early in CKD.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

The researchers enrolled CKD stage III-IV patients who had 25-hydroxyvitamin D (25-OH-D) level <30 ng/mL.

How the Study Was Run

The design is described as randomized.

Because people in this Parathyroid Hormone (PTH 1-84) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The researchers compared serum 25-OH-D, intact-PTH, phosphate, calcium, and bone biomarker levels, during the 8-week intervention.

What Was Measured

Vitamin D deficiency/insufficiency is common in chronic kidney disease (CKD) patients and it contributes to secondary hyperparathyroidism, which occurs early in CKD.

PubMed files the paper under topics including Calcium, Ergocalciferols, Hyperparathyroidism, Secondary, Parathyroid Hormone, Phosphates, Renal Insufficiency, Chronic and Vitamin D.

What This Means in Plain Language

The paper is a randomized study of Parathyroid Hormone (PTH 1-84).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Journal of the Medical Association of Thailand = Chotmaihet thangphaet), a journal based in Thailand.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.